Premium
Engineering Cardiac Tissues from Pluripotent Stem Cells for Drug Screening and Studies of Cell Maturation
Author(s) -
Miklas Jason W.,
Nunes Sara S.,
Radisic Milica
Publication year - 2013
Publication title -
israel journal of chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.908
H-Index - 54
eISSN - 1869-5868
pISSN - 0021-2148
DOI - 10.1002/ijch.201300064
Subject(s) - induced pluripotent stem cell , cardiac hypertrophy , tissue engineering , chemistry , stem cell , human induced pluripotent stem cells , microbiology and biotechnology , cardiac cell , cell , embryonic stem cell , muscle hypertrophy , neuroscience , biomedical engineering , biology , biochemistry , medicine , endocrinology , gene
Using cardiomyocytes derived from human pluripotent stem cells (hPSC‐CMs), it is now possible to develop models of human cardiac diseases and to screen novel pharmaceutical agents on human cardiac cells and tissues. However, since hPSC‐CMs display an immature phenotype, significant focus has turned to cardiac tissue engineering to deliver a means to mature these cells. In this review we discuss the maturation state of currently available hPSC‐CMs and provide an overview of the processes involved in cardiomyocyte maturation. We then explore the differences between pathological and physiological hypertrophy and discuss how tissue engineering techniques that rely on the combined use of biomaterials and bioreactors can be utilized to enhance and study the hypertrophic response.